Background
Autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematous, occur when the body attacks its own tissue because it cannot differentiate between self and non-self. This is mainly through deregulation of the immune system. Vitamin D has been known to play a critical role in bone mineralization and bone health. Activated vitamin D is a hormone that plays a role in calcium and phosphorus absorption.1 More recently, studies have shown that vitamin D also has receptors in the bone marrow and thymus, where the immune system develops and matures.3,4 T cells in the thymus, once activated, increase vitamin D receptors fivefold.5 Activated vitamin D has been shown to inhibit interleukin 6 (IL-6), an inflammatory cytokine.1 The Iowa Women’s Health Study showed rheumatoid arthritis disease risk and vitamin D intake were inversely related.6 Another study has shown disability and RA to be inversely related to vitamin D intake. Thus, based on the studies reviewed regarding vitamin D and RA, it’s important to keep vitamin D at a sufficient level for RA patients.
In our federally qualified health center (FQHC), most of the patients are underinsured or uninsured; thus, most patients with RA are unable to follow up with private rheumatologists.
Objective
The question addressed in this quality-improvement project was to ascertain whether patients with RA at our FQHC are getting their vitamin D checked at least once a year and where their levels fall.
Method
A retrospective chart review was performed. Patients were identified using clinic encounters with an associated ICD-9 code for RA (714.0) in the EMR at our FQHC, from Jan. 1, 2012, through Dec. 31, 2014. Charts were searched for lab work results and/or documentation of a vitamin D order during the past year (2014). The level of vitamin D was identified in one of four categories: deficient (<20 ng/mL), insufficient (20–30 ng/mL), sufficient (30–100 ng/mL) and toxic (>100 ng/mL).
Results
A total of 104 patients with RA were identified, of which 91 were included. The 13 excluded did not have encounters or lab work performed in 2014. Of those included, 28.5% of patients had their vitamin D checked at least once during the year. Two patients had documentations that indicated vitamin D deficiency, but lab work with the exact numbers was not available. Of those who had their vitamin D checked, 30.7% had levels that were deficient, 34.6% had insufficient levels and 26.9% had sufficient levels. No patient had a toxic level of vitamin D.
Discussion
RA is the most common autoimmune disease, and it is a chronic inflammatory process that affects the joints most often, but RA also has extra-articular manifestations.8 According to the ACR Classification Criteria for Rheumatic Diseases, the criteria for RA diagnosis include morning stiffness of more than one hour on most mornings for at least six weeks; arthritis and soft tissue swelling of more than three of the 14 joints, present for least six weeks; positive rheumatoid factor and/or anti-cyclic citrullinated peptide, elevated C-reactive protein or erythrocyte sedimentation rate.2,10 Core measures in assessing RA are primarily to evaluate joint inflammation and the rheumatologist’s global assessment.
Vitamin D plays an essential role in calcium absorption, but also has an immunomodulatory role through vitamin D receptors. Activated vitamin D inhibits the expression of IL-6, thus decreasing inflammation.
The etiology of RA is still unknown, but progress in the pathophysiology of RA has shown that increased production of tumor necrosis factor (TNF-alpha) is a key protein involved in synovial inflammation and joint destruction. Some studies have shown that increased production of TNF-alpha plays a key role in the synovial inflammation and joint destruction. TNF-alpha activates IL-6, which causes inflammation and joint destruction. Another study shows TNF-alpha, IL-1 and IL-6 through their inflammatory effects cause osteoclast activation in RA patients. IL-6 stimulates Th17 cells and results in inflammation and joint destruction. Interestingly, studies have shown that activated vitamin D inhibits the expression of IL-6.1 Additionally, long-term steroid treatment and disease-modifying anti-rheumatic drugs can cause a decrease in bone formation and weaken bones overall, thus increasing the risk of fracture in RA patients.11
Vitamin D plays an essential role in calcium absorption, but also has an immunomodulatory role through vitamin D receptors.1,7 Activated vitamin D inhibits the expression of IL-6, thus decreasing inflammation.1 The most recent recommendations by the National Committee for Quality Assurance/Physician Consortium for Performance Improvement (PCPI) advocate TB screening, periodic assessment of disease activity, glucocorticoid treatment and functional status assessment, and indicate that prescribing vitamin D is an integral part of clinical decision making. Thus, in RA patients, it is vital to check and maintain vitamin D at a sufficient level.
In our FQHC, although we may not prescribe biologics, such as etanercept, as primary care physicians, we can monitor and maintain vitamin D at a sufficient level in RA patients. Given that vitamin D plays an important role in anti-inflammation, we need to make sure we are following patients’ vitamin D levels closely. Additionally, vitamin D, along with other measures, such as weight-bearing exercises, is important for patients with RA to preserve bone health, which is important in the prevention of fractures. A vitamin D supplement, if necessary, is affordable for RA patients at all socioeconomic levels.
Currently, based on this chart review for quality measure, our FQHC is suboptimal at checking vitamin D levels in our RA patients; they are being checked only 28.5% of the time—meaning they are not checked 71.5% of the time. Of those who had vitamin D levels checked, 70% of the patients had deficient or insufficient levels, thus requiring supplements. Further, documentation of whether or not deficient or insufficient levels were replaced was not uniform.
Conclusion
Vitamin D has a key role in the inflammatory process, thus playing an important role in autoimmune diseases, such rheumatoid arthritis. In our federally qualified health clinic, where many of our patients are underinsured or uninsured, patients may not follow up with a rheumatologist. Although we may not manage biological medications, as primary care physicians, we can address patients’ RA inflammation and bone health through vitamin D. We can check their vitamin D levels at least once a year and prescribe the supplement to keep it at a sufficient level. Better adherence to RA guidelines, goals of disease management and documentation is required. This may be achieved through such interventions as physician (resident) education and use of clinical reminders in the FQHC, both of which are underway at this time.
Dewan Kazi Fahima, DO, a graduate of UMDNJ-SOM, is now a third-year internal medicine resident at Monmouth Medical Center, Long Branch, N.J. She hopes to join the rheumatology field soon as a fellow.
Rafah Salloum, MD, is a rheumatology attending at Monmouth Medical Center, Long Branch, N.J.
References
- Cutolo M, Otsa K, Uprus M, et al. Vitamin D in rheumatoid arthritis. Autoimmun Rev. 2007 Nov;7(1):59–64. Epub 2007 Aug 14.
- Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569–2581. doi: 10.1002/art.27584.
- Deluca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. FASEB J. 2001 Dec;15(14):2579–2585.
- Langub MC, Reinhardt TA, Horst RL, et al. Characterization of vitamin D receptor immunoreactivity in human bone cells. Bone. 2000 Sep;27(3):383–387.
- Mahon BD, Wittke A, Weaver V, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem. 2003 Aug 1;89(5):922–932.
- Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women’s Health Study. Arthritis Rheum. 2004 Jan;50(1):72–77.
- Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: New etiological and therapeutical considerations. Ann Rheum Dis. 2007 Sep;66(9):1137–1142. Epub 2007 Jun 8.
- Lee R. Diseases of musculoskeletal system. In Nutrition Therapy and Pathophysiology, 1st ed. (2007) Nelms M, Sucher K, Long S (eds). Belmont, Calif: Thomson Brooks/Cole. pp. 843–879.
- Scott D, Wolfe F, Huizinga T. Rheumatoid arthritis. Lancet. 2010 Sep 25;376(9746):1094–1108. doi: 10.1016/S0140-6736(10)60826-4.
- Vonkeman HE, Van de Laar MA. The new European League Against Rheumatism/American College of Rheumatology diagnostic criteria for rheumatoid arthritis: How are they performing? Curr Opin Rheumatol. 2013 May;25(3):354–359. doi: 10.1097/BOR.0b013e32835f6928.
- Grossman J, Gordon R, Ranganath V, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1515–1526. doi: 10.1002/acr.20295.